Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19

Abstract

The WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group IMPORTANCE Effective therapies for patients with coronavirus disease 2019 (COVID-19) are needed, and clinical trial data have demonstrated that low-dose dexamethasone reduced mortality in hospitalized patients with COVID-19 who required respiratory support.OBJECTIVE To estimate the association between administration of corticosteroids compared with usual care or placebo and 28-day all-cause mortality. DESIGN, SETTING, AND PARTICIPANTSProspective meta-analysis that pooled data from 7 randomized clinical trials that evaluated the efficacy of corticosteroids in 1703 critically ill patients with COVID-19. The trials were conducted in 12 countries from February 26, 2020, to June 9, 2020, and the date of final follow-up was July 6, 2020. Pooled data were aggregated from the individual trials, overall, and in predefined subgroups. Risk of bias was assessed using the Cochrane Risk of Bias Assessment Tool. Inconsistency among trial results was assessed using the I 2 statistic. The primary analysis was an inverse variance-weighted fixed-effect meta-analysis of overall mortality, with the association between the intervention and mortality quantified using odds ratios (ORs). Random-effects meta-analyses also were conducted (with the Paule-Mandel estimate of heterogeneity and the Hartung-Knapp adjustment) and an inverse variance-weighted fixed-effect analysis using risk ratios.EXPOSURES Patients had been randomized to receive systemic dexamethasone, hydrocortisone, or methylprednisolone (678 patients) or to receive usual care or placebo (1025 patients). MAIN OUTCOMES AND MEASURESThe primary outcome measure was all-cause mortality at 28 days after randomization. A secondary outcome was investigator-defined serious adverse events.RESULTS A total of 1703 patients (median age, 60 years [interquartile range, 52-68 years]; 488 [29%] women) were included in the analysis. Risk of bias was assessed as "low" for 6 of the 7 mortality results and as "some concerns" in 1 trial because of the randomization method. Five trials reported mortality at 28 days, 1 trial at 21 days, and 1 trial at 30 days. There were 222 deaths among the 678 patients randomized to corticosteroids and 425 deaths among the 1025 patients randomized to usual care or placebo (summary OR, 0.66 [95% CI, 0.53-0.82]; P < .001 based on a fixed-effect meta-analysis). There was little inconsistency between the trial results (I 2 = 15.6%; P = .31 for heterogeneity) and the summary OR was 0.70 (95% CI, 0.48-1.01; P = .053) based on the random-effects meta-analysis. The fixed-effect summary OR for the association with mortality was 0.64 (95% CI, 0.50-0.82; P < .001) for dexamethasone compared with usual care or placebo (3 trials, 1282 patients, and 527 deaths), the OR was 0.69 (95% CI, 0.43-1.12; P = .13) for hydrocortisone (3 trials, 374 patients, and 94 deaths), and the OR was 0.91 (95% CI, 0.29-2.87; P = .87) for methylprednisolone (1 trial, 47 patients, and 26 deaths). Among the 6 trials that repo...

A living WHO guideline on drugs for covid-19

“…To create recommendations, the panel relied on evidence synthesised in a living network meta-analysis led by MAGIC,3 on a prospective meta-analysis of RCTs evaluating corticosteroids for critically ill COVID-19 patients commissioned by the WHO,6 as well as systematic reviews of the safety of similar regimens of systemic corticosteroids in distinct but relevant patient populations 78. While the investigators responsible for meta-analyses rate the certainty of the evidence, this is re-assessed independently by the guideline panel.…”

“…A preliminary report of the RECOVERY trial in June 2020 suggested that dexamethasone reduced mortality in covid-19 patients, with a subgroup analysis suggesting the benefit to be restricted to patients with severe and critical covid-19 11. This evidence was complemented by new data from six randomised trials of corticosteroids reporting mortality data by subgroup in a prospective meta-analysis of randomised trials for corticosteroid therapy for covid-19 6. The data were made immediately available for the guideline panel, allowing the WHO guidance to be peer reviewed and published simultaneously with the prospective meta-analysis and three of the individual trials 121314…”

“…On 17 July 2020 the panel reviewed evidence from eight RCTs (7184 patients) evaluating systemic corticosteroids versus usual care in treatment of covid-19,6 of which seven reported mortality data by subgroup of illness severity. (Mortality data from one trial, GLUCOCOVID, were not incorporated in the Summary of Finding for mortality because the mortality outcome data was not available by subgroup).…”

Genetic determinants of COVID-19 drug efficacy revealed by genome-wide CRISPR screens

“…It is used to treat many types of autoimmune diseases and hematological malignancies. Multiple studies demonstrated its efficacy in lowering death rate of COVID-19 patients 4–6 . As a cell line of B lymphocyte lineage, Eμ-Myc;Arf−/− cell serves as an ideal platform for interrogating dexamethasone’s immunosuppressive mechanism.…”

Covid-19: Hydrocortisone can be used as alternative to dexamethasone, review finds

“…The WHO Rapid Evidence Appraisal for Covid-19 Therapies (REACT) Working Group conducted a meta-analysis of seven trials that evaluated corticosteroids (mainly hydrocortisone or dexamethasone) in 1703 critically ill patients in 12 countries from 26 February to 9 June 2020, with final follow-up on 6 July 1…”